Physician profile
Deepthy Varghese
NPI 1194182857
$7,437.68
in general payments reported to CMS, 2019-2025
26 companies · $811 in 2025
The $811 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,232 · 2022: $1,755 · 2023: $1,588 · 2024: $2,052 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,450.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,205.20 | 2021-2025 | Aveir, Ensite Precision, Tacticath Ablation Catheter, Sensor Enabled |
| Boston Scientific Corporation | $1,100.90 | 2021-2025 | Watchman Flx, General - Therapies, General - Pain Management |
| Amgen INC. | $471.40 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $369.43 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $300.04 | 2021-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $288.44 | 2021-2025 | Micra, Affera Mapping System |
| Biotronik INC. | $244.55 | 2021-2023 | |
| Cvrx, INC. | $151.26 | 2024-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $147.44 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $131.44 | 2021-2024 | Farxiga, Wainua |
| Pfizer INC. | $128.81 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $122.67 | 2024 | Ultomiris |
| Novo Nordisk INC | $119.38 | 2022 | |
| Daiichi Sankyo INC. | $106.87 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $93.83 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $88.44 | 2021-2024 | Verquvo |
| Heartflow, INC. | $85.59 | 2022-2024 | Ffrct |
| Novartis Pharmaceuticals Corporation | $76.41 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.43 | 2021-2023 | Jardiance |
| Cardiva Medical, INC. | $36.82 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $23.64 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $23.48 | 2022 | |
| B. Braun Interventional Systems INC. | $21.66 | 2024 | Na |
| Convatec INC. | $18.14 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.63 | 2024 | Opsumit |
| Impulse Dynamics (USA) INC. | $12.78 | 2023 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthy Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.